Almond Christopher S D, Thiagarajan Ravi R, Piercey Gary E, Gauvreau Kimberlee, Blume Elizabeth D, Bastardi Heather J, Fynn-Thompson Francis, Singh T P
Department of Cardiology (C.S.D.A., R.R.T., G.E.P., K.G., E.D.B., H.J.B., T.P.S.), Cardiac Surgery (F.F.T.), and the Pediatric Transplant Center (C.S.D.A., E.D.B., H.J.B., F.F.T., T.P.S.), Children's Hospital Boston; the Department of Pediatrics, Harvard Medical School; and the Department of Biostatistics (K.G.), Harvard School of Public Health; all in Boston, Mass.
Circulation. 2009 Feb 10;119(5):717-727. doi: 10.1161/CIRCULATIONAHA.108.815712. Epub 2009 Jan 26.
Children listed for heart transplantation face the highest waiting list mortality in solid-organ transplantation medicine. We examined waiting list mortality since the pediatric heart allocation system was revised in 1999 to determine whether the revised allocation system is prioritizing patients optimally and to identify specific high-risk populations that may benefit from emerging pediatric cardiac assist devices.
We conducted a multicenter cohort study using the US Scientific Registry of Transplant Recipients. All children <18 years of age who were listed for a heart transplant between 1999 and 2006 were included. Among 3098 children, the median age was 2 years (interquartile range 0.3 to 12 years), and median weight was 12.3 kg (interquartile range 5 to 38 kg); 1294 (42%) were nonwhite; and 1874 (60%) were listed as status 1A (of whom 30% were ventilated and 18% were on extracorporeal membrane oxygenation). Overall, 533 (17%) died, 1943 (63%) received transplants, and 252 (8%) recovered; 370 (12%) remained listed. Multivariate predictors of waiting list mortality include extracorporeal membrane oxygenation support (hazard ratio [HR] 3.1, 95% confidence interval [CI] 2.4 to 3.9), ventilator support (HR 1.9, 95% CI 1.6 to 2.4), listing status 1A (HR 2.2, 95% CI 1.7 to 2.7), congenital heart disease (HR 2.2, 95% CI 1.8 to 2.6), dialysis support (HR 1.9, 95% CI 1.2 to 3.0), and nonwhite race/ethnicity (HR 1.7, 95% CI 1.4 to 2.0).
US waiting list mortality for pediatric heart transplantation remains unacceptably high in the current era. Specific high-risk subgroups can be identified that may benefit from emerging pediatric cardiac assist technologies. The current pediatric heart-allocation system captures medical urgency poorly. Further research is needed to define the optimal organ-allocation system for pediatric heart transplantation.
在实体器官移植医学中,等待心脏移植的儿童面临着最高的等待名单死亡率。我们研究了自1999年儿科心脏分配系统修订以来的等待名单死亡率,以确定修订后的分配系统是否对患者进行了最佳优先排序,并识别可能从新兴的儿科心脏辅助装置中获益的特定高危人群。
我们使用美国移植受者科学注册系统进行了一项多中心队列研究。纳入了1999年至2006年间所有登记等待心脏移植的18岁以下儿童。在3098名儿童中,年龄中位数为2岁(四分位间距0.3至12岁),体重中位数为12.3千克(四分位间距5至38千克);1294名(42%)为非白人;1874名(60%)被列为1A状态(其中30%使用呼吸机,18%使用体外膜肺氧合)。总体而言,533名(17%)死亡,1943名(63%)接受了移植,252名(8%)康复;370名(12%)仍在等待名单上。等待名单死亡率的多变量预测因素包括体外膜肺氧合支持(风险比[HR] 3.1,95%置信区间[CI] 2.4至3.9)、呼吸机支持(HR 1.9,95% CI 1.6至2.4)、1A状态(HR 2.2,95% CI 1.7至2.7)、先天性心脏病(HR 2.2,95% CI 1.8至2.6)、透析支持(HR 1.9,95% CI 1.2至3.0)以及非白人种族/族裔(HR 1.7,95% CI 1.4至2.0)。
在当前时代,美国儿科心脏移植等待名单死亡率仍然高得令人无法接受。可以识别出可能从新兴的儿科心脏辅助技术中获益的特定高危亚组。当前的儿科心脏分配系统对医疗紧迫性的把握不佳。需要进一步研究来确定儿科心脏移植的最佳器官分配系统。